Bio-Techne Corporation

The Beneish M-Score of -3.079 is below the -1.78 threshold, and the label places it outside the elevated manipulation-risk zone. In plain terms, this screen did not flag the reported figures for closer review, but a screen is not proof that the statements are accurate. The Altman Z-Score here is the Z-double-prime version, at 5.89, which falls in the safe zone; the model's distress screen places the company well above its threshold for that zone. The Piotroski F-Score is 5 of 8 computable signals, a reading in the middle of the range that summarizes profitability, leverage, and efficiency tests rather than a pass or fail grade. Scores are built only from reported numbers and cannot see everything. Several filing items deserve a careful read. The 10-Q reports no material legal proceedings as of May 6, 2026. The repurchase plan approved April 30, 2025 authorizes up to $400 million, yet the filing states $405.0 million was available to repurchase as of March 31, 2026, a discrepancy readers may want to check against the full filing. A director's Rule 10b5-1 plan adopted March 4, 2026 provides for the sale of up to 10,396 shares between June 3, 2026 and February 26, 2027. The exhibit list also includes an Executive Transition Agreement with Dr. Matt McManus dated March 1, 2026, which readers may want to review for leadership context. Taken together, the strongest signals in these filings are the sharp drop in profit despite growth and the acquisition-dependent expansion strategy, rather than any score-based red flag.

Catalyst.According to the fiscal 2025 annual figures, revenue rose 5.2% year over year to $1.22 billion, from $1.16 billion in fiscal 2024. The business description ties the company's growth strategy largely to acquisitions and investments, citing the Spear Bio investment at the start of fiscal 2025, the Lunaphore acquisition at the start of fiscal 2024, and a 19.9% stake in Wilson Wolf completed in fiscal 2023, with the remaining ownership due by the end of calendar 2027. The Protein Sciences segment represented about 72% of fiscal 2025 net sales and the Diagnostics and Spatial Biology segment about 28%. The 10-Q excerpt provided covers mainly forward-looking statement language and does not itemize the quarter's revenue drivers, so the current catalyst is best read from the annual filing.

Hidden risk.The most material tension is the gap between top-line growth and earnings. Net income fell from $168.1 million in fiscal 2024 to $73.4 million in fiscal 2025, a decline of about 56%, and operating income fell from $206.69 million to $102.25 million, about 50%. The operating cash flow to net income ratio of 3.92 looks strong, but it is high mainly because net income is low; operating cash flow itself slipped from $298.98 million to $287.56 million. Equity also declined from $2.07 billion to $1.92 billion. The 10-Q states there were no material changes to risk factors, so readers may want to look at the acquisition integration and facility construction items in the forward-looking statement list.